Dicerna-Novo Nordisk deal revealed: DRNA stock pops 78% in premarket

Follow us on Google News:
 Dicerna-Novo Nordisk deal revealed: DRNA stock pops 78% in premarket
Image source: Guschenkova, Shutterstock

Highlights

  • Novo Nordisk will acquire Dicerna Pharmaceuticals for US$3.3 billion.
  • After the acquisition, Novo expects to begin the clinical development of its first investigational therapeutic in 2022.
  • The transaction, which would be debt-financed, is expected to close in the fourth quarter of 2021.

Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) jumped more than 78% in the premarket session on Thursday, November 18, after the Danish pharmaceutical major Novo Nordisk A/S (NYSE: NVO) announced plans to buy Dicerna.

The DRNA stock traded at US$37.97 at 8:54 am ET, up 78.43% from their previous close.

The Lexington, Massachusetts-based biotechnology firm announced on Thursday that it has entered into a definitive agreement to sell itself to Novo Nordisk.

Novo Nordisk has agreed to acquire Dicerna for US$3.3 billion or US$38.25 per share at a premium of 80% to Decerna's Wednesday closing price in a cash deal. The transaction has been approved unanimously by the board of directors of both companies.

Also Read: Seven HOT building material stocks: Are they worth your penny?

Dicerna Pharmaceuticals (DRNA) has said that it entered into a definitive agreement with Novo Nordisk to sell itself to the Danish pharmaceutical major.

Also Read: Sono, Rivian & Canoo: Which firms are leading the EV market race?

Dicerna-Novo Nordisk Partnership

The two healthcare companies have been working together in research projects using Dicerna's ribonucleic acid interference (RNAi) therapeutics since 2019.

They were researching the therapeutics to counteract the genes that cause or trigger diseases. In addition, the companies have also worked together on clinical candidates for conditions like chronic liver illness, obesity, non-alcoholic steatohepatitis (NASH), etc.

Novo Nordisk said in a statement that this acquisition would aid the firm in developing and applying a wide range of "technology platforms across all Novo Nordisk therapeutics areas". In addition, after the acquisition, Novo expects to begin the clinical development of its first investigational therapeutic in 2022.

Also Read: Braze IPO: BRZE stock jumps 36% in market debut. How to buy it?

Company stock highlights and financials:

Dicerna has a market cap of US$1.65 billion, with an EPS of US$-1.63. Its 52-week highest and lowest stock prices were US$40.14 and US$19.06, respectively. The DRNA stock tumbled 3.58% YTD. The company reported a net loss of US$17.07 million on revenue US$62.95 million in Q3, FY21, compared to a loss of US$21.84 million on revenue US$48.87 million a year ago.

Also Read: Bitcoin mining firm Iris Energy IPO: Here’s how you can buy IREN stock

Bottomline

The transaction, which would be debt-financed, is expected to close in the fourth quarter of 2021. Meanwhile, the acquisition will not affect the full-fiscal 2021 guidance of Novo Nordisk but may cause a 3% decline in its 2022 operating profit growth, according to Reuters. Meanwhile, the S&P 500 healthcare sector surged 17.59% YTD while increasing by 4.91% QTD.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles